Understand the source comparison
Peptides for Acne Treatment Protocol Evidence Guide Comparison
LL-37 Peptide (1.5%) Membrane disruption + immune modulation 6–8 weeks Minimal. Transient stinging in 12% of users Phase III RCT (n=214) Best-tolerated antimicrobial option for inflammatory acne; comparable efficacy to retinoids Benzoyl Peroxide (2.5–5%) Oxida
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- LL-37 Peptide (1.5%)
- Membrane disruption + immune modulation
- 6–8 weeks
- Minimal. Transient stinging in 12% of users
- Phase III RCT (n=214)
- Best-tolerated antimicrobial option for inflammatory acne; comparable efficacy to retinoids
- Benzoyl Peroxide (2.5–5%)
- Oxidative bacterial kill + keratolysis
- 4–6 weeks
- Dryness (45%), peeling (38%), contact dermatitis (15%)
- Meta-analysis of 47 RCTs
- Fastest-acting but highest irritation risk; triggers compensatory sebum rebound
- Adapalene (0.3%)
- Retinoid receptor agonism (comedolysis)
- 8–12 weeks
- Photosensitivity (52%), barrier disruption (41%)
- Phase III RCT, FDA-approved
- Gold standard for comedonal acne; requires 3-month commitment before full effect
- β-Defensin 2 (0.5%)
- Selective C. acnes inhibition
- 6–10 weeks
- Minimal. Mild dryness in 8%
- Phase II trial (n=84)
- Strong antimicrobial but lacks barrier repair; best as combination therapy
- Niacinamide (4%) + Peptide
- Sebum regulation + AMP activity
- 8–10 weeks
- Minimal. Flushing in 6% at doses >5%
- Combination trial (UC Derm 2020)
- Dual-mechanism approach with additive benefits and no additive irritation